EGFR and head and neck squamous cell carcinoma: Specifically, glycosylated PD-L2 combine with epidermal growth factor receptor (EGFR) in the cytomembrane to suspend the effect of its inhibitor, cetuximab, in HNSCC (the specific mechanism on the post-translational regulation section) [23].